Literature DB >> 28486359

Minimally Invasive Hysterectomy and Power Morcellation Trends in a West Coast Integrated Health System.

Eve Zaritsky1, Lue-Yen Tucker, Romain Neugebauer, Tatiana Chou, Tracy Flanagan, Andrew J Walter, Tina Raine-Bennett.   

Abstract

OBJECTIVE: To examine trends in minimally invasive hysterectomy and power morcellation use over time and associated clinical characteristics.
METHODS: We conducted a trend analysis and retrospective cohort study of all women 18 years of age and older undergoing hysterectomy for benign conditions at Kaiser Permanente Northern California collected from electronic health records. Generalized estimating equations and Cochran-Armitage testing were used to assess the primary outcomes, hysterectomy incidence, and proportion of hysterectomies by surgical route and power morcellation. Logistic regression analysis was used to assess secondary outcomes, clinical characteristics, and complications associated with surgical route.
RESULTS: There were 31,971 hysterectomies from 2008 to 2015; the incidence decreased slightly from 2.86 (95% confidence interval [CI] 2.85-2.87) to 2.60 (95% CI 2.59-2.61) per 1,000 women (P<.001). Minimally invasive hysterectomies increased from 39.8% to 93.1%, almost replacing abdominal hysterectomies entirely (P<.001). Vaginal hysterectomies decreased slightly from 26.6% to 23.4% (P<.001). The proportion of nonrobotic laparoscopic hysterectomies with power morcellation increased steadily from 3.7% in 2008 to a peak of 11.4% in 2013 and decreased to 0.02% in 2015 (P<.001). Robot-assisted laparoscopic hysterectomies remained a small proportion of all hysterectomies comprising 7.8% of hysterectomies in 2015. Women with large uteri (greater than 1,000 g) were more likely to receive abdominal hysterectomies than minimally invasive hysterectomy (adjusted relative risk 11.62, 95% CI 9.89-13.66) and laparoscopic hysterectomy with power morcellation than without power morcellation (adjusted relative risk 5.74, 95% CI 4.12-8.00). Laparoscopic supracervical hysterectomy was strongly associated with power morcellation use (adjusted relative risk 43.89, 95% CI 37.55-51.31).
CONCLUSION: A high minimally invasive hysterectomy rate is primarily associated with uterine size and can be maintained without power morcellation.

Entities:  

Mesh:

Year:  2017        PMID: 28486359     DOI: 10.1097/AOG.0000000000002034

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Outcomes of Robotic Hysterectomy for Treatment of Benign Conditions: Influence of Patient Complexity.

Authors:  Lisa J Herrinton; Tina Raine-Bennett; Liyan Liu; Stacey E Alexeeff; Wilfredo Ramos; Betty Suh-Burgmann
Journal:  Perm J       Date:  2019-12-18

2.  Racial Disparities in Route of Hysterectomy for Benign Indications Within an Integrated Health Care System.

Authors:  Eve Zaritsky; Anthonia Ojo; Lue-Yen Tucker; Tina R Raine-Bennett
Journal:  JAMA Netw Open       Date:  2019-12-02

3.  Safety Warning about Laparoscopic Power Morcellation in Hysterectomy: A Cost-Effectiveness Analysis of National Impact.

Authors:  Xiao Xu; Vrunda B Desai; Peter E Schwartz; Cary P Gross; Haiqun Lin; Maria J Schymura; Jason D Wright
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-03-28

4.  Risk Factors Associated with Perineal and Vaginal Lacerations and Vaginal Removal in Total Laparoscopic Hysterectomy.

Authors:  Kenro Chikazawa; Ken Imai; Hiroyoshi Ko; Naoki Ichi; Masahiro Misawa; Tomoyuki Kuwata
Journal:  Gynecol Minim Invasive Ther       Date:  2022-08-05

5.  Postoperative Urinary Retention after Benign Gynecologic Surgery with a Liberal versus Strict Voiding Protocol.

Authors:  Matthew T Siedhoff; Kelly N Wright; Meenal A Misal; Andrea L Molina; Naomi H Greene
Journal:  J Minim Invasive Gynecol       Date:  2020-07-08       Impact factor: 4.137

6.  Complication Rate of Laparoscopic Hysterectomies in Denmark, 2011-2016.

Authors:  Olav Istre; Dorthe Snejbjerg
Journal:  JSLS       Date:  2018 Jan-Mar       Impact factor: 2.172

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.